Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2026

Jhaveri K L, Neven P, Casalnuovo M L, Kim S-B, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey L A, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang X A, Cao S, Bidard F C

Abstract excerpt

BACKGROUND: At the primary progression-free survival (PFS) analysis, the phase III EMBER-3 trial in endocrine therapy-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant versus standard of care (SOC: fulvestrant or exemestane) in patients with ESR1 mutations (ESR1m)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Benzimidazoles

Share to Breast Neoplasms

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Estrogen Receptor alpha

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 41391667
DOI: 10.1016/j.annonc.2025.11.018
PMCID: PMC13485152

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.PMID 41391667Read ↗

Oral SERDs: Transforming the treatment of advanced breast cancer-Insights from EMBER-3.Semantic proximity Read ↗

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and SafetySemantic proximity Read ↗

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.Semantic proximity Read ↗

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read ↗

Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 TrialSemantic proximity Read ↗

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read ↗

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatmentSemantic proximity Read ↗

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programSemantic proximity Read ↗

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.Semantic proximity Read ↗

Elacestrant in metastatic breast cancer: current advancements and future perspectives.Semantic proximity Read ↗

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.Semantic proximity Read ↗

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.